stoxline Quote Chart Rank Option Currency Glossary
Pyxis Oncology, Inc. (PYXS)
3.94  0.25 (6.78%)    07-23 16:00
Open: 3.72
High: 3.97
Volume: 652,296
Pre. Close: 3.69
Low: 3.62
Market Cap: 232(M)
Technical analysis
2024-07-23 4:54:42 PM
Short term     
Mid term     
Targets 6-month :  4.63 1-year :  5.41
Resists First :  3.97 Second :  4.63
Pivot price 3.19
Supports First :  3.25 Second :  2.8
MAs MA(5) :  3.52 MA(20) :  3.19
MA(100) :  4.27 MA(250) :  3.13
MACD MACD :  0 Signal :  -0.2
%K %D K(14,3) :  91 D(3) :  76.5
RSI RSI(14): 64.8
52-week High :  6.84 Low :  1.35
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PYXS ] has closed Bollinger Bands are 10.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.98 - 3.99 3.99 - 4.01
Low: 3.58 - 3.6 3.6 - 3.61
Close: 3.91 - 3.94 3.94 - 3.97
Company Description

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 17 Jul 2024
Susquehanna Fundamental Investments LLC Invests $351,000 in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

Tue, 16 Jul 2024
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Tue, 16 Jul 2024
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $8.80 Consensus Price Target from Analysts - MarketBeat

Fri, 28 Jun 2024
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Thu, 20 Jun 2024
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$25m market cap decline as longer-term profits stay in the green - Yahoo Finance

Mon, 10 Jun 2024
Pyxis Oncology: Promising Research Amid Cash Constraints (NASDAQ:PYXS) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 59 (M)
Shares Float 39 (M)
Held by Insiders 19.8 (%)
Held by Institutions 46.4 (%)
Shares Short 2,310 (K)
Shares Short P.Month 2,190 (K)
Stock Financials
EPS -1.38
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.13
Profit Margin 0 %
Operating Margin -29.8 %
Return on Assets (ttm) -20 %
Return on Equity (ttm) -34.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.27
EBITDA (p.s.) -1.05
Qtrly Earnings Growth 0 %
Operating Cash Flow -65 (M)
Levered Free Cash Flow -29 (M)
Stock Valuations
PE Ratio -2.88
PEG Ratio -0.1
Price to Book value 1.25
Price to Sales 14.36
Price to Cash Flow -3.6
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android